The term "latency" is often applied to infections caused by herpesviruses, wherein viral replication and disease manifestations appear concordantly after long intervals of silence. In the case of the human immunodeficiency virus (HIV), an asymptomatic period of "clinical latency" can intervene between infection and the development of the acquired immune deficiency syndrome (AIDS). Freedom from symptoms does not, however, imply an absence of viral replication. Recent experiments studying the kinetics of viral turnover have estimated that, in patients with CD4 counts of 500 or less, 10~-109 virions are produced per day, resulting in a peripheral viremia of 104-107 RNA molecules/ml and in the destruction of approximately 2 x 109 CD4 ÷ T cells/day (Ho et al., 1995; Wei et al., 1995) . Most (>98%) of the plasma virus is apparently produced within recently infected cells, with little contribution from chronically infected cells or from latently infected cells that then become activated. On the basis of these studies, the possibility has been raised that the kinetics of viral and cellular turnover found in late-stage disease may persist from the outset, leading ultimately to immune system collapse and AIDS (Coffin, 1995) . If so, then cells with latent viral genomes may be inconsequential to disease progression.
This view of "virological mayhem" (Wain-Hobson, 1995) may be correct, but it is currently an inference. The kinetics of viral and cell turnover in late-stage disease were deduced upon perturbation of the steady state with combinations of antiretroviral compounds. For populations of patients with early-stage and asymptomatic disease, data from such an intervention have yet to be reported. Indeed, this phase of disease appears to be associated not simply with clinical latency, but also with easily detectable levels of cells with latent viral genomes. In this review, previous findings on viral latency in HIV disease are discussed in relation to emerging paradigms of persistent and high level viral replication and cytopathicity.
Quantitative Changes in Virus Load During Disease Progression
In most HIV-infected patients, the absolute level of viremia may fluctuate, but active virus replication clearly persists throughout the disease course. The acute viral syndrome that sometimes follows primary exposure is associated with high peak levels of cell-associated and cell-free virus in the peripheral blood (Clark et al., 1991; Daar et al., 1991; Graziosi et al., 1993) . Most patients thereafter move into an asymptomatic phase of disease in which absolute levels of HIV RNA in the peripheral blood are lower but still demonstrable (Piatak et al., 1993) . Even at times when detectable virus in the peripheral circulation is at a nadir, high levels of virus replication and of "trapped" extracellular virus (e.g., on follicular dendritic cells) are found within lymphoid organs (Fox et al., 1991; Pantaleo et al., 1991 Pantaleo et al., , 1993 Embretson et al., 1993a) . As measu red by infectious virus titers and levels of p24 antigen or viral nucleic acid, there is a positive correlation between clinical stage and the absolute level of virus replication (Coombs et al., 1989; Ho et al., 1989; Schnittman et al., 1991; Michael et al., 1992; Piatak et al., 1993) . This is true whether the measurements are performed in peripheral blood or within hematolymphoid organs. The latter, however, tend to be preferential sites for replication and the repository of most CD4 ÷ cells in the body. It is within these organs, presumably, that most virus replication occurs.
Latency at the Cellular Level
Though HIV replication may be chronically persistent within infected individuals, cells carrying latent genomes are also found. This point was perhaps best demonstrated in studies of HIV-infected chimpanzees: active viral replication was detected in lymphoid organs, while cells with transcriptionally silent but inducible HIV genomes circulated in the peripheral blood (Saksela et al., 1993) . Such latency is likely associated with the fact that most CD4 ÷ cells are resting in vivo, a function of strong checks on cell division within the hematopoietic system. Formally, two latent states have been envisioned for the viral genome.
Preintegration Latency
Like other lentiretroviruses, HIV may bind to and enter quiescent target cells (Stevenson et al., 1990a; Zack et al., 1990) . With participation from nuclear localizing signals on the viral proteins Vpr and matrix, the viral preintegration complex is actively transported through the nucleopore (Bukrinsky et al., 1993; Heinzinger et al., 1994; von Schwedler et al., 1994; Gallay et al., 1995) . In terminally differentiated macrophages and cells that are arrested in the GI/ S or G2 phases of the cell cycle, HIV replication can occur after proviral integration (Weinberg et al., 1991; Lewis et al., 1992; Lewis and Emerman, 1994) . In contrast, integration does not occur within T lymphocytes that are in the GO phase of the cell cycle. Extrachromosomal replicative intermediates remain unintegrated in the cell for a limited period of hours to days (Zack et al., 1990; Stevenson et al., 1990a) and, although the data are controversial (Sakai et al., 1993) , may even serve as competent templates for the production of HIV-1 core and envelope proteins (Stevenson et al., 1990b) . Until and unless the cell is activated, proviral integration and virus production do not occur.
Since CD4 ÷ cells are normally quiescent in vivo, preintegration latency in T cells may occur frequently within the HIV-infected patient. Unintegrated viral DNA has indeed been documented both within quiescent peripheral blood T cells (Bukrinsky et al., 1991) and in microglial cells of the central nervous system (Pang et al., 1990) . In the former case, these genomes were shown to retain the ability to integrate after activation of the host cell. However, the half-life of the unintegrated genome is short, relative to the estimated division time of resting T cells in vivo (McLean and Michie, 1995) , and the stable integration of such genomes in vivo is likely a rare event.
Postintegration Latency
The human T lymphoblastoid cell line, ACH-2, and the myeloid line, U 1, harbor integrated viral genomes in a minimally productive state and have sewed as in vitro models for postintegration latency. Upon exposure of these lines to tumor necrosis factor (~ (TNFa) and phorbol esters, virus production occurs via NF-KB-mediated induction of the HIV-1 long terminal repeat (Dub et al., 1989; Folks et al., 1989; Griffin et al., 1989) . Early studies indicated that cells within these lines express multiply spliced transcripts associated with viral regulatory gene products in the absence of full-length genomic RNA (Pomerantz et al., 1990) . This "blocked early-stage latency" pattern of transcription in vitro, equivalent to the early stages of a lytic infection (Kim et al., 1989) , was postulated to be maintained by limiting intracellular levels of the viral regulatory protein Rev. This situation approximates the state of latency previously shown for lentiretroviruses such as visna virus, in which large numbers of infected cells produce viral RNA but not virus (Gendelman et al., 1985) .
Different mechanisms of latency have been documented within these cell line models. Latency in U1 cells appears to result, at least in part, from a relative deficiency of Tat in the cellular environment (Chen et al., 1994) and is associated with an accumulation of promoter-proximal viral transcripts (Adams et al., 1994) . Provision of Tat protein overcomes the latent state (Cannon et al., 1994; Duan et al., 1994) . In contrast, critical determinants of latency in ACH-2 appear to reside at the site of integration (Winslow et al., 1993; Chen et al., 1994) , and very low levels of transcription in this line are not up-regulated by exogenous Tat protein (Cannon et al., 1994; Duan et al., 1994) .
In HIV-infected patients, cells carrying integrated provirus in a latent state are readily demonstrable. Early studies indicated that cells with latent genomes were 10-to 100-fold more abundant than those actively replicating viral RNA (Harper et al., 1986; McEIrath et al., 1989; Schnittman et al., 1989) . Among infected cells in which HIV was transcriptionally active, many were found to not produce viral structural gene products (Namikawa et al., 1988) . Subsequent studies using a variety of assays (including standard in situ hybridization as well as flow cytometry and polymerase chain reactiondriven detection of viral DNA and RNA in situ) confirmed a high frequency of cells carrying viral DNA in vivo and a correspondingly low frequency of cells actively transcribing viral RNA Embretson et al., 1993a Embretson et al., , 1993b Pantaleo et al., 1993; Patterson et al., 1993; Lebargy et al., 1994) . These observations were made in lymphoid and myeloid cells obtained from peripheral blood, lymphoid organs, and by bronchoalveolar lavage. In accordance with the in vitro model systems for HIV latency, peripheral blood cells obtained from HIV ÷ patients were found in some (Michael et al., 1992; Seshamma et al., 1992) but not all studies to exhibit "blocked early-stage latency," with a predominance of multiply spliced over unspliced or singly spliced viral RNAs. HIV-infected cells with a bias toward promoter-proximal transcripts were also observed (Adams et al., 1994) .
As a special case, some integrated genomes may be defective and replication incompetent. In at least one instance, such defects have been associated with a prolonged state of clinical well-being and mapped to mutations in the nef gene (Kirchhoff et al., 1995) . Although undocumented, it is conceivable that production of viral gene products, if not viral progeny, from such genomes could have deleterious effects to the host cell, neighboring cells, or both.
Balancing Latency and Replication in Vivo
Data from the above studies broadly define four cell populations in the H IV-infected host: one that actively produces virus, another that carries latent proviral genomes, a third that carries defective proviral genomes, and a fourth that differentiates and/or proliferates to compensate for losses within the former populations. Since these cell populations reside primarily in hematolymphoid organs, it is difficult to measure their size and turnover. The recent studies of viral turnover by Wei et al. (1995) and Ho et al. (1995) provide some estimates in late-stage disease (see above). To date, however, no firm estimates of the size and relative proportions of these populations are available for earlystage HIV disease (i.e., when peripheral blood CD4 counts are greater than 500 and circulating viral loads less than 104 RNA molecules/ml). It is only evident that stable numbers of circulating CD4 ÷ T cells can be observed du ring this "clinically latent" period. To understand how this balance is maintained and possibly lost, it is instructive to consider its formation.
Irrespective of the route of introduction, the initial inoculure of HIV is likely to be small and focally deposited within lymphoreticular tissue that drains the port of entry (McCune, 1991) . Since the virus carries many antigenic epitopes (and may be accompanied by allogeneic cells and other potent polyclonal activators), the immunocompetent host will mount an immune response involving interactions between antigen-presenting cells, T cells, and B cells. Paradoxically, CD4 + T cell activation during these responses will create favorable conditions for infection, integration, and dissemination of HIV (Pope et al., 1994) . Viral spread may occur because the cell is productively infected. Alternatively, naive CD4 + T cells may move through one round of division, integrate proviral genomes, and then remain quiescent as CD4 ÷ memory cells. If so, the potential for viral spread will move with the cell itself.
The total body deposition of virus during acute infection will be determined in part by the rate of viral replication and the counterposing effectiveness of the antiviral immune response. At its end, a fraction of the CD4 + target cell population will carry HIV genomes. Ongoing virus production will occur in some of these cells (e.g., macrophages and activated T cells). This fraction of cells may rapidly turn over and, in the process, establish an ever-expanding cohort of secondarily infected target cells. Such a scenario would be consistent with the dynamics of viral replication and cell turnover observed in late stages of disease. However, since most infected target cells will be quiescent, HIV genomes at this time may instead be deposited predominantly within a state of preintegration latency (e.g., in the case of infected T cells that have not divided) or postintegration latency (e.g., in the case of T cells that have divided at least once postinfection). These latent genomes will have differential stability: those that are unintegrated may be degraded quickly and lost from the cell; those that are integrated could potentially remain for the lifetime of the quiescent cell.
Changes in the total body load of HIV will thereafter be determined, in part, by the rate of clearance of productively infected cells, the rate of virus release from these cells, and the rate by which cells with latent genomes are cleared. In some infected patients, disease progression after the acute viral syndrome occurs slowly, if at all (Cao et al., 1995; Pantaleo et al., 1995) . In a few patients, virus may even be cleared entirely (Clerici et al., 1992; RowlandJones et al., 1993; Bryson et al., 1995) . The mechanisms underlying these phenomena are poorly understood, but could include slow or defective viral replication, the development of rapidly effective antiviral immune responses, or both.
Cellular Latency Lost
Several correlations suggest that disease progression is associated with a relative change in the proportion of cells carrying latent genomes and of those that actively replicate virus. First, the putative mechanisms for cellular latency have been most readily observed in cross-sectional studies of patients with early, asymptomatic disease. Secondly, prospective studies have revealed a time-dependent loss of cellular latency as disease progresses. In peripheral blood mononuclear cells, advancing disease was predated by a qualitative change from no to measurable or from predominantly spliced to unspliced (Michael et al., 1995) viral RNA production. By analogy with studies of lymphoid organs (Embretson et al., 1993a; Pantaleo et al., 1993) , this may reflect an even greater shift away from latency within lymphoid compartments.
This shift may occur because the physiological environment of progressive HIV disease disfavors the maintenance of quiescent cells carrying latent genomes. Exposure to antigenic challenges (e.g., chronic parasitic infections, common colds, and even vaccinations) will prompt cellular proliferation and viral replication. Besides stimulating specific immune responses (and thereby clonally activating CD4 + T cells), infectious agents may also shift the balance between latent and productive infection by triggering the production of cytokines that can up-regulate HIV replication (e.g., interleukin-1 or TNFa) (Poli and Fauci, 1992) . In some cases (e.g., the CD4 ÷ T tropic human herpesvirus 6), direct transactivation of the otherwise latent HIV genome can also occur (Kashanchi et al., 1994) .
Once initiated, the various endogenous and exogenous signals leading to cell activation will drive a self-perpetuating and slowly progressive loop. Movement of a cell toward viral replication is associated with the production of the following: vitally encoded proteins capable of driving de novo immune responses; Tat, which can drive the production of cytokines (e.g., TNFa) (Sastry et al., 1990) and secondarily up-regulate virus production in other latently infected cells Kitano et al., 1993) ; Vpr, which can up-regulate viral replication in T cells and macrophages (Levy et al., 1995) ; Nef, which can render viral particles more infectious (Miller et al., 1994) . Each of these influences will serve to expand the population of productively infected cells.
Since most productively infected cells appear to have a short iifespan (Ho et al., 1995; Wei et al., 1995) , constant levels of CD4 + cells in the peripheral blood must be maintained by enhanced hematopoietic activity. This could occur upon accelerated differentiation and proliferation of early hematopoietic progenitor cells in the bone marrow or thymus and/or by proliferation of clonally dispersed T cells in the periphery. In either case, feedback stimulation on the hematopoietic system will have mixed effects. The generation of functional cells de novo serves to restore the peripheral immune system; reciprocally, moving more CD4 ÷ hematopoietic cells into cycle will create a larger pool of cells susceptible to HIV infection and destruction. At the level of the primitive multilineage hematopoietic stem cell, some of the very cytokines that up-regulate virus production (e.g., TNF~, TGFI~, and interferon-y) can also serve to suppress multilineage hematopoiesis .
Interesting twists to the above dynamics are presented by hosts with less functional immune systems, e.g., the HIV-infected fetus. In comparison with the immunocompetent adult, immune system activation will not be as widespread: exogenous antigens are absent and infection of the thymus may even induce a state of tolerance toward HIV. Predictably, most CD4 ÷ T cells will be quiescent at birth and latent proviral genomes should prevail within them. In contrast, a higher proliferative mass is likely to be found in the hematopoietic progenitor cell compartment of the developing fetus. CD4 + cells in this group of progenitors (e.g., CD3-CD4+CD8 -intrathymic T progenitors) may accordingly be more susceptible to productive infection and destruction by HIV (Suet al., 1995) .
Concluding Remarks
The cellular dynamics of HIV disease are complex: infected cells with productive or latent genomes can coexist even in the absence of apparent signs or symptoms. Cells with latent genomes may represent a minor fraction of the total number of infected cells or may often carry defective genomes. If so, they may constitute an unimportant reservoir for virus spread in vivo, at least as extrapolated from a "steady-state" analysis of late-stage disease (Coffin, 1995) . Alternatively, since asymptomatic HIV disease may be associated with fewer proliferative signals (e.g., from opportunistic infections, induced cytokines, etc.), resting cells with latent, replication-competent genomes may prevail during the early stages of disease. These genomes may then be induced toward viral production as disease progresses. With further rounds of viral replication and mutation, it is possible that this compartment of resting cells may later carry a predominance of genomes that are either defective or, alternatively, resistant to the action of antiviral compounds.
Discrimination between these possiblities will be important for the rational design of treatment protocols for HIV disease. Should cells with actively replicating virus be abundant and persistent throughout the course of disease, a plausible argument may be made for early and aggressive therapy with combinations of effective antiretroviral compounds. This approach would, of course, be less compelling if latent genomes predominate during early stages of disease.
At this juncture in our analysis of HIV pathogenesis, it is important to analyze carefully and quantitatively the contribution that various populations of HIV-infected cells may make toward disease progression. Where are these cells located? What state of latency do they maintain? How many are there? How long do they persist? What is their relative representation among the total infected population of cells? Having addressed these questions in adults, are there significant differences found in HIVinfected infants? Answers to these questions should help to clarify the role, if any, that cellular latency may play in HIV disease.
